Objective: This study aimed to evaluate the impact of cinobufacini capsules in patients who underwent total thyroidectomy for differentiated thyroid cancer (DTC).
Methods: A prospective cohort study was conducted, and a total of 120 DTC patients were selected. The patients were divided into two groups: a control group receiving standard postoperative treatment (n = 60) and a cinobufacini group receiving cinobufacini capsules in addition to standard treatment (n = 60). Various assessments were conducted, including pain evaluation, lymphocyte subset measurement, as well as the quantification of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), free sulfhydryl (-SH) levels, and lipid hydroperoxides (LOOH) in serum.
Results: Both groups experienced reduced pain levels after one month of treatment, with the cinobufacini group demonstrating a more significant reduction. In comparison to the control group, one month of cinobufacini treatment resulted in substantial increases in NK cell activity, percentages of NK cells, activated NK cells, and CD8+ T-cells. It also led to the mitigation of oxidative stress and inflammation response.
Conclusions: These findings indicate that cinobufacini may serve as an adjunctive therapy for DTC patients, offering benefits in pain management, immune modulation, and reducing inflammation and oxidative stress after surgery.